France-based Servier has completed its acquisition of the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) for up to USD 2.65 billion, securing global rights to sevasemten, a late-stage oral fast skeletal myosin inhibitor with pivotal Becker muscular dystrophy data expected in Q4 2026. The deal, which closed on July 13, 2026 following regulatory clearance, marks Servier's entry into rare neuromuscular disease.
The transaction comprises USD 1.55 billion in upfront cash and up to USD 1.1 billion in regulatory and commercial milestone payments. Individual milestone triggers were not disclosed. Servier acquired global rights to sevasemten, while employees primarily supporting the muscular dystrophy program received offers to transition to the company. Edgewise retains its cardiovascular pipeline, including EDG-7500, a cardiac sarcomere modulator in Phase II development for hypertrophic cardiomyopathy, and EDG-15400 for heart failure with preserved ejection fraction, with the USD 1.55 billion upfront expected to fully fund EDG-7500 through potential approval.
Sevasemten is an oral, potentially first-in-class fast skeletal myosin inhibitor designed to reduce contraction-induced muscle damage associated with absent or dysfunctional dystrophin. The 175-participant GRAND CANYON pivotal cohort is fully enrolled, with topline results expected in Q4 2026. Sevasemten also holds FDA Orphan Drug and Fast Track designations for both BMD and Duchenne muscular dystrophy (DMD), Rare Pediatric Disease Designation for DMD, and EMA Orphan Drug Designations for both indications. If approved in BMD, it would be the first therapy indicated for that condition. Servier will also continue Phase II development in DMD, where sevasemten is intended to offer a mutation-agnostic approach that could be used across a broad patient population.